Stock Scorecard



Stock Summary for BridgeBio Pharma Inc (BBIO) - $22.49 as of 11/20/2024 7:48:20 PM EST

Total Score

3 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BBIO

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BBIO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BBIO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BBIO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BBIO (38 out of 90)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0

Latest News for for BBIO

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - BridgeBio Pharma ( NASDAQ:BBIO ) 11/19/2024 7:44:00 PM
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months 11/18/2024 4:15:00 PM
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia - BridgeBio Pharma ( NASDAQ:BBIO ) 11/18/2024 10:30:00 AM
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia 11/18/2024 10:30:00 AM
BridgeBio Pharma ( BBIO ) Reports Q3 Loss, Lags Revenue Estimates 11/12/2024 1:45:00 PM
Amphastar Pharmaceuticals ( AMPH ) Lags Q3 Earnings and Revenue Estimates 11/6/2024 10:35:00 PM
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management - BridgeBio Pharma ( NASDAQ:BBIO ) 11/5/2024 12:30:00 PM
BridgeBio Pharma ( BBIO ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release 10/31/2024 2:01:00 PM
3 Top Stocks That Could Still Rocket Higher in 2024 10/4/2024 9:17:00 AM
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - BridgeBio Pharma ( NASDAQ:BBIO ) 10/3/2024 11:30:00 AM

Financial Details for BBIO

Company Overview

Ticker BBIO
Company Name BridgeBio Pharma Inc
Country USA
Description BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 22.49
Price 4 Years Ago 71.11
Last Day Price Updated 11/20/2024 7:48:20 PM EST
Last Day Volume 2,148,572
Average Daily Volume 1,695,229
52-Week High 44.32
52-Week Low 21.62
Last Price to 52 Week Low 4.02%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -10.65
Free Cash Flow Ratio 15.95
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 3.19
Total Cash Per Share 1.41
Book Value Per Share Most Recent Quarter -6.51
Price to Book Ratio 123.68
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 19.56
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 7

Share Statistics

Total Shares Outstanding 188,990,000
Market Capitalization 4,250,385,100
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -33.67%
Reported EPS 12 Trailing Months -2.42
Reported EPS Past Year -1.45
Reported EPS Prior Year -3.94
Net Income Twelve Trailing Months -438,860,000
Net Income Past Year -643,202,000
Net Income Prior Year -481,183,000
Quarterly Revenue Growth YOY -33.20%
5-Year Revenue Growth -26.45%
Operating Margin Twelve Trailing Months -68.50

Balance Sheet

Total Cash Most Recent Quarter 266,324,000
Total Cash Past Year 434,884,000
Total Cash Prior Year 471,922,000
Net Cash Position Most Recent Quarter -1,451,275,000
Net Cash Position Past Year -1,291,845,000
Long Term Debt Past Year 1,726,729,000
Long Term Debt Prior Year 1,707,615,000
Total Debt Most Recent Quarter 1,717,599,000
Equity to Debt Ratio Past Year -3.64
Equity to Debt Ratio Most Recent Quarter -2.52
Total Stockholder Equity Past Year -1,354,257,000
Total Stockholder Equity Prior Year -1,254,617,000
Total Stockholder Equity Most Recent Quarter -1,229,922,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -456,325,000
Free Cash Flow Per Share Twelve Trailing Months -2.41
Free Cash Flow Past Year -529,026,000
Free Cash Flow Prior Year -425,815,000

Options

Put/Call Ratio 0.22
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.17
MACD Signal -0.06
20-Day Bollinger Lower Band 22.38
20-Day Bollinger Middle Band 25.84
20-Day Bollinger Upper Band 29.30
Beta 1.09
RSI 39.93
50-Day SMA 29.33
150-Day SMA 19.57
200-Day SMA 28.08

System

Modified 11/20/2024 6:55:56 PM EST